Stock·NASDAQ·Industrials
Cintas Corporation (CTAS)
- Market cap
- $84.85B
- P/E
- 42.15
- Dividend yield
- 0.88%
- Street target
- $224.50median of 20 analysts
- 52-week range
- $161.16 $219.17
The short version
Where CTAS stands today, in four lines, and what CleaRank Financial AI makes of it.
CTAS at a glance
Cintas Corporation (CTAS): Buy, 67/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($201.05 and $188.79).
- Earnings CTAS beat estimates in 4 of its last 6 quarters, yet fell the next day after 1 of those beats.
- Insiders Insiders sold $8.5M and bought $267K over the last 18 months.
- Valuation P/E of 42.1 against 34.0 for the Industrials sector: a premium to peers (+24%).
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates Cintas Corporation (CTAS) Buy, with a model score of 67/100.
The trend lifts the score most: the price is 13.20% above its 200-day average and 6.30% above its 50-day average, and the 50-day average is 6.49% above the 200-day. Valuation holds it back most: the P/E of 42.15 is 24.0% above the sector median (a premium to peers) and the P/S of 7.34 is 83.5% above the sector median. The 50-day average stands at $201.05 and the 200-day at $188.79. Over the past year the price rose 15.92%.
Only on CleaRank
Figures we compute ourselves from CTAS's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $213.71 is 6.3% above the 50-day simple moving average of $201.05.Price above its 200-day average ›
The price is 13.2% above the 200-day simple moving average of $188.79.50-day average above the 200-day ›
The 50-day average ($201.05) is 6.5% above the 200-day average ($188.79), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 91% of its 52-week range, between $161.16 and $219.17.
CTAS share price
Pick a period: each tab shows how far CTAS has moved over it, to the last close.
Today's trading
Where CTAS sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
3/5P/E below the sector median ›
The trailing P/E of 42.15 is 24.0% above the Industrials median of 34.0.P/S below the sector median ›
The price-to-sales ratio of 7.34 is 83.5% above the sector median of 4.0.Profitable over the last 12 months ›
Net income over the last 12 months was $2.1B on revenue of $11.6B, a net margin of 17.8%.Beat estimates in most recent reports ›
CTAS beat the EPS estimate in 4 of its last 6 reports.Pays a dividend ›
The trailing dividend yield is 0.88%, or $1.87 a share a year.
Key statistics
The headline figures for CTAS.
As of October 17, 2026, CTAS trades at $213.71, with a market value of $84.85B, a P/E ratio of 42.15 and a dividend yield of 0.88%.
What the numbers say
CleaRank Financial AI's reading of CTAS's valuation, growth and risks.
CTAS trades at 42.15 times trailing earnings, which places its P/E 24.0% above the Industrials median of 34.0. The peer comparison on this page puts that multiple in the range of a premium to peers. On sales, the P/S of 7.34 stands 83.5% above the sector median of 4.0. Its market value is $84.9B, and trailing earnings come to $5.07 per share.
Over the latest year revenue expanded 10.90%, which leaves it 0.8 percentage points behind the Industrials sector median of 11.7%. Profitability is strong: the net margin is 17.82%, the operating margin is 24.10%, and the return on equity of 41.38% is above the sector median of 17.8%. Debt-to-equity stands at 0.52. The trailing dividend yield is 0.88%, or $1.87 per share each year.
In its most recent report, on September 23, 2026, CTAS posted EPS of $1.36 against an estimate of $1.36, missing the estimate by 0.00%. The market reacted the other way, with the stock rising 2.97% the following session.
The company has beaten estimates in 4 of the last 6 reports, yet the stock fell in the first session after 1 of those 4 beats. Analysts expect EPS of $5.54 for this fiscal year, a rise of 12.2%, and $6.16 for the year after, a rise of 11.2%.
Valuation leaves less margin for error: the P/E of 42.15 is 24.0% above the sector median, a premium to peers. Normal swings for CTAS run at about 1.27% a day. Over the last 18 months, insider sales totalled $8.5M against $267K of purchases; planned sales and tax sales on vesting shares make selling a weaker signal than buying.
CTAS against the Industrials sector
How CTAS compares with the median Industrials stock CleaRank tracks.
Price to earnings vs sector: CTAS trades at a significant premium to sector peers (+24%), suggesting market expectations for superior growth or market position.
Return vs XLI: Since May 6, 2025, CTAS has gained 0.2% against a gain of 25.7% for XLI.
Performance against XLI
CTAS and the Industrials sector fund over the same days.
Revenue and earnings
How much CTAS sells, and how much of it becomes profit.
Revenue growth: Revenue grew 8.9% in FY2026 to $11.3B, from $10.3B a year earlier.
Profit margin: The net margin was 17.8% in FY2026, up from 17.5% the year before.
Profitable: CTAS earned $2.0B in FY2026.
Earnings reality check
Did CTAS beat what analysts expected, and how did the stock react?
Earnings record: CTAS beat the analyst estimate in 4 of the last 6 quarters.
Market reaction: The stock fell in the first session after 1 of those 4 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Sep 23, 2026after close | $1.36 | $1.36 | +0.00% | +2.97% | +1.61% |
| Dec 18, 2025after close | $1.19 | $1.21 | +1.68% | -1.22% | +0.66% |
| Sep 24, 2025after close | $1.20 | $1.20 | +0.00% | +1.00% | +1.80% |
| Jul 17, 2025after close | $1.07 | $1.09 | +1.87% | +0.01% | +0.43% |
| Mar 26, 2025after close | $1.06 | $1.13 | +6.60% | +0.75% | +1.93% |
| Dec 19, 2024after close | $1.02 | $1.09 | +6.86% | +2.27% | +0.32% |
As of October 17, 2026, CTAS has beaten the analyst EPS estimate in 4 of its last 6 reported quarters and fell in the first trading session after 1 of those beats; its latest report, on September 23, 2026, came in 0.00% above the estimate and the stock moved +2.97% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
2/3RSI not overbought or oversold ›
The 14-day RSI is 71.6, in overbought territory.RSI above 50 ›
An RSI of 71.6 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of CTAS
The score, the reasoning behind it, and what could move the price next.
Cintas Corporation (CTAS) is trading in an uptrend. The price of $213.71 sits 6.30% above its 50-day average of $201.05 and 13.20% above its 200-day average of $188.79. Sitting at 91% of its 52-week range, the price is 2.49% below the 52-week high of $219.17. The 50-day average is 6.49% above the 200-day average, which means the shorter trend is pulling ahead of the longer one.
On momentum, the 14-day RSI reads 71.6, in overbought territory, with the MACD line positive. Every period on the chart shows a gain, with the price up 4.53% over the past three months, 19.28% over the past six months and 15.92% over the past year.
Earnings miss ›
The September 23, 2026 report missed the EPS estimate by 0.00%, and the share price rose 2.97% in the first session after it.
Source: Earnings report, September 23, 2026
Rating reaffirmed ›
Citigroup kept its Sell rating on September 30, 2026.
Source: Analyst action, Citigroup, September 30, 2026
- Two levels matter most right now: the 52-week high at $219.17 above the price, and the 20-day EMA at $202.83 below it.
- A 14-day RSI of 71.6 places the stock in the overbought zone, and the MACD line is positive. Readings above 70 or below 30 point to stretched momentum.
- Following the September 23, 2026 report, the share price climbed 2.97% in the first session. Over the last 6 reports, CTAS beat estimates in 4.
CTAS trades above its 50-day and 200-day moving averages ($201.05 and $188.79), which is what makes the trend up; losing the 50-day would be the first warning. The nearest level under the price is the 20-day EMA at $202.83.
CTAS has the 52-week high at $219.17 as its next overhead level. The RSI sits in overbought territory, so a pause would not by itself break the trend. A slide back out of the bullish zone would be the sign that momentum is fading.
Technical indicators
Momentum and trend for CTAS, from its daily closes.
As of October 17, 2026, with CTAS at $213.71, its 14-day RSI is 71.6 (overbought territory), its 50-day simple moving average is $201.05 and its 200-day is $188.79.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What CTAS moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, CTAS's 1-year correlation of daily returns is +0.36 with S&P 500 (SPY), +0.21 with Nasdaq 100 (QQQ), -0.06 with Bitcoin (BTC) and +0.04 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
1/3Most analysts rate it a buy ›
10 of 20 analysts rate it a buy or strong buy, 9 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $224.50 is 5.0% above the price.More buy ratings than three months ago ›
10 of 20 rate it a buy now, against 10 of 20 three months ago.
CTAS Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 30, 2026 | Citigroup | Maintains | Sell |
| Sep 29, 2026 | Argus Research | Maintains | Buy |
| Sep 24, 2026 | UBS | Maintains | Buy |
| Sep 24, 2026 | Baird | Maintains | Outperform |
| Sep 24, 2026 | Truist Securities | Maintains | Buy |
| Sep 24, 2026 | RBC Capital | Reiterates | Sector Perform |
As of October 17, 2026, 20 Wall Street analysts cover CTAS: 10 rate it a buy or strong buy, 9 a hold and 1 a sell or strong sell. Their 12-month price targets range from $181.00 to $250.00, with a median of $224.50, 5.0% above the price of $213.71.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
CTAS trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Long entry pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from CTAS's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much CTAS tends to move, against the market and on its own.
The long record
CTAS's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
4/4Average daily move under 2% ›
The price has moved 1.27% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 44.5%, from February 2020 to April 2020, regained by August 2020.Most 1-year holds ended higher ›
87% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $87,960, against $42,058 in the S&P 500 (SPY).
CTAS Drawdowns & Recovery
As of October 17, 2026, CTAS's worst peak-to-trough fall over the last 10 years with dividends reinvested was -44.5% (February 2020 to April 2020); it regained that peak by August 2020, 4 months after the low, and 87% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into CTAS in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: CTAS beat the S&P 500 over this period: $87,960 against $42,058.
A $10,000 investment in CTAS in October 2016 would be worth about $87,960 today with dividends reinvested, compared with about $42,058 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to CTAS, and which have not.
Strongest month, July: an average of +9.20%, up in 9 of 10 years.
Weakest month, March: an average of -3.18%, up in 5 of 10 years.
This month, October: has averaged +0.36%, up in 5 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, CTAS's strongest calendar month has been July (average +9.20%, up in 9 of 10 years) and its weakest March (average -3.18%, up in 5 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in CTAS, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CTAS today could grow to about $27,558 by 2036 in the base case, with a 90th-percentile outcome near $81,868 and a 10th-percentile outcome around $9,277. The simulation models price only; at today's 0.88% yield, dividends would add to these figures. Projections are statistical simulations, not guarantees.
CTAS Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $321 for CTAS by 2030 in the base case, from $214 today (1.5x over 4 years). The 10th-percentile path ends near $161. These are outcomes of a Monte Carlo simulation run on CTAS's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $168 | $237 | $334 | |
| 2028 | $161 | $262 | $426 | |
| 2029 | $160 | $290 | $526 | |
| 2030 | $161 | $321 | $638 | |
| 2031 | $164 | $355 | $766 |
Method: a lognormal simulation of CTAS's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
CTAS insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $267K on the open market and sold $8.5M.
As of October 17, 2026, CTAS insiders reported 5 open-market sales worth $8.5M and 1 open-market purchase worth $267K over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Aug 10, 2026 | David Brock Denton
General Counsel
|
Grant | 5.7K | $1.2M |
| Aug 10, 2026 | Scott D Farmer
Officer and Director
|
Grant | 830 | $168.2K |
| Aug 10, 2026 | Scott Garula
Chief Financial Officer
|
Grant | 10.7K | $2.2M |
| Aug 10, 2026 | James Rozakis
President
|
Grant | 11.3K | $2.3M |
| Aug 10, 2026 | Todd M Schneider
Chief Executive Officer
|
Grant | 57.9K | $11.7M |
| Jul 22, 2026 | Ronald William Tysoe
Director
|
Sell | 4.4K | $872.2K |
| Jul 22, 2026 | Ronald William Tysoe
Director
|
Option | 5.0K | $136.8K |
| Jul 16, 2026 | Melanie W Barstad
Director
|
Sell | 9.1K | $1.9M |
| Jul 16, 2026 | Melanie W Barstad
Director
|
Option | 10.5K | $285.9K |
| Apr 20, 2026 | Ronald William Tysoe
Director
|
Sell | 4.7K | $834.6K |
| Apr 20, 2026 | Ronald William Tysoe
Director
|
Option | 5.5K | $149.1K |
| Apr 9, 2026 | Robert E Coletti
Director
|
Option | 12.5K | $339.5K |
| Jan 28, 2026 | Robert E Coletti
Director
|
Grant | 5.2K | - |
| Jan 28, 2026 | Scott D Farmer
Officer, Director and Beneficial Owner
|
Grant | 10.4K | - |
| Dec 23, 2025 | Robert E Coletti
Officer and Director
|
Grant | 14.0K | - |
| Dec 23, 2025 | Scott D Farmer
Officer, Director and Beneficial Owner
|
Grant | 29.0K | - |
| Oct 29, 2025 | Melanie W Barstad
Director
|
Grant | 503 | - |
| Oct 29, 2025 | Beverly K Carmichael
Director
|
Grant | 503 | - |
| Oct 29, 2025 | Karen L Carnahan
Director
|
Grant | 503 | - |
| Oct 29, 2025 | Robert E Coletti
Officer and Director
|
Grant | 503 | - |
| Oct 29, 2025 | Martin Mucci
Director
|
Grant | 503 | - |
| Oct 29, 2025 | Joseph M Scaminace
Director
|
Grant | 503 | - |
| Oct 29, 2025 | Ronald William Tysoe
Director
|
Grant | 503 | - |
| Aug 11, 2025 | David Brock Denton
General Counsel
|
Grant | 4.6K | $1.0M |
| Aug 11, 2025 | Scott D Farmer
Officer, Director and Beneficial Owner
|
Grant | 976 | $218.5K |
| Aug 11, 2025 | Scott Garula
Chief Financial Officer
|
Grant | 4.4K | $995.8K |
| Aug 11, 2025 | James Rozakis
Chief Operating Officer
|
Grant | 6.9K | $1.5M |
| Aug 11, 2025 | James Rozakis
Chief Operating Officer
|
Option | 46.0K | $4.1M |
| Aug 11, 2025 | Todd M Schneider
Chief Executive Officer
|
Grant | 46.4K | $10.4M |
| Jul 30, 2025 | Ronald William Tysoe
Director
|
Sell | 5.1K | $1.1M |
| Jul 28, 2025 | Todd M Schneider
Chief Executive Officer
|
Sell | 17.3K | $3.8M |
| Jul 28, 2025 | Todd M Schneider
Chief Executive Officer
|
Option | 52.2K | $4.7M |
| Jul 21, 2025 | Martin Mucci
Director
|
Buy | 1.2K | $267.1K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.